H. Tesch

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer Interdisziplinäre

U. Nöthlings, A. Schneeweiss, J. Huober, 2022 .

Update Breast Cancer 2022 Part 1 – Early Stage Breast Cancer

M. Lux, P. Fasching, T. Fehm, 2022, Geburtshilfe und Frauenheilkunde.

Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study.

T. Fehm, C. Denkert, H. Tesch, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer

M. Lux, P. Fasching, T. Fehm, 2022, Geburtshilfe und Frauenheilkunde.

Gain study: A phase III trial to compare ETC versus EC-TX and ibandronate versus observation in patients with node-positive primary breast cancer.

R. Kreienberg, H. Tesch, S. Loibl, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The REMAR (Rhein-Main-Registry) real-world study: prospective evaluation of the 21-gene breast recurrence score® assay in addition to Ki-67 for adjuvant treatment decisions in early-stage breast cancer

D. Giesecke, U. Hurst, L. Anastasiadou, 2024, Breast cancer research and treatment.

CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs

N. Ditsch, M. Ruebner, V. Thewes, 2023, Geburtshilfe und Frauenheilkunde.

Update Breast Cancer 2023 Part 3 – Expert Opinions of Early Stage Breast Cancer Therapies

M. Lux, A. Schneeweiss, N. Harbeck, 2023, Geburtshilfe und Frauenheilkunde.